Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,064.01
(
-0.63%
)
US TECH 100
25,899.60
(
0.11%
)
Dow Jones
49,149.38
(
-0.60%
)
Brent Oil
93.70
(
-1.38%
)
Bitcoin
77,991.77
(
2.18%
)
News Focus
News Focus
Post# of 822358
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Dr Bala

Send PM Follow Ignore
Followers 98
Posts 7202
Boards Moderated 0
Alias Born 03/29/2019

Dr Bala

Re: exwannabe post# 534291

Thursday, 11/17/2022 3:30:42 PM

Thursday, November 17, 2022 3:30:42 PM

Post# of 822358

Conclusions
This phase 3, nonrandomized, externally controlled trial found
that the addition of DCVax-L to SOC was associated with a clinically
meaningful and statistically significant extension of overall
survival in both nGBM and rGBM. Treatment with DCVax-L
also had an excellent safety profile and noteworthy tails of long-term
survival curves.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent NWBO News
More NWBO News